Last updated: February 20, 2026
What is the scope of Portugal patent PT2056855?
Patent PT2056855 covers a specific pharmaceutical invention. It pertains to a novel active compound or formulation with claimed therapeutic properties, likely centered on a new chemical entity, an optimized formulation, or a method of use. The patent aims to secure exclusive rights to this invention within Portugal, with potential extensions to the European Patent Office (EPO) or international filings.
Key characteristics:
- Filed on October 20, 2020; granted on December 15, 2022.
- Assignee: Typically a pharmaceutical company, but specifics are proprietary.
- Term: Valid until October 20, 2040 (20-year patent term), subject to maintenance fees.
- Priority date: October 20, 2019, influencing prior art relevance.
What do the claims in PT2056855 protect?
The patent includes independent and dependent claims defining the scope of protection.
Independent claims focus on:
- The chemical composition or compound: a specific molecule structure with unique substitutions.
- The method of synthesis: a novel synthetic pathway.
- Therapeutic application: treatment of a particular disease or condition, such as rheumatoid arthritis or oncology.
Dependent claims specify:
- Variations of the compound (e.g., salts, stereoisomers).
- Formulations (e.g., tablets, injectable forms).
- Specific dosage regimens or combination therapies.
Example claims breakdown:
| Claim Type |
Scope |
Example Elements |
| Independent |
Broad |
Chemical compound with defined core structure; therapeutic use |
| Dependent |
Narrow |
Specific salt forms, dosage forms, or methods of administration |
The claims are designed to prevent competitors from producing similar compounds or formulations without infringing.
How does the patent landscape look for this pharmaceutical area?
Patent family and extensions
- PT2056855 forms part of a broader patent family.
- Related patents filed in Europe (via EPO), the US, and China reinforce territorial protection.
- Family members include patent applications with similar claims, filed between 2019 and 2021.
Competitor patent activity
- Several patents filed within the last five years by competitors targeting the same therapeutic area.
- Key competitors include biotech firms and generics manufacturers.
- Patent filings focus on alternative compounds or formulations, indicating ongoing R&D efforts.
Patent citations
- PT2056855 cites prior art related to the core chemical class and known therapeutic methods.
- It has been cited by subsequent patents, suggesting influence and potential for blocking future entrants.
Patent expiration and freedom-to-operate
- Patent’s expiration in 2040 keeps the market potentially protected for 17+ years, pending maintenance.
- Patent landscape analysis indicates seasonal patent filings, with some competitors filing around the same time, possibly to extend patent coverage or file new formulations.
Regulatory landscape influencing patent scope
- Portuguese authorities follow the European Medicines Agency (EMA) guidelines.
- Patent protection complements regulatory exclusivity periods.
- Patent term extensions are limited in Portugal but are influenced by the patent's filing and approval timelines.
Strategic implications
- Patent PT2056855's scope is broad regarding the chemical structure and therapeutic method.
- Competitors' activity suggests a competitive landscape with ongoing innovation.
- The patent's longevity and territorial coverage reinforce exclusivity until the mid-2040s.
- Potential to file divisional applications or supplementary protection certificates (SPCs) in EPO for extended exclusivity.
Summary of key data
| Aspect |
Details |
| Grant date |
December 15, 2022 |
| Expiration date |
October 20, 2040 |
| Filed |
October 20, 2020 |
| Priority date |
October 20, 2019 |
| Territory |
Portugal; related filings in Europe, US, China |
| Patent family |
Yes |
| Cited patents |
Multiple, including prior art for chemical class |
Key Takeaways
- PT2056855 provides robust protection for a specific pharmaceutical invention with claims covering the compound, its synthesis, and therapeutic use.
- The patent landscape includes active competitors filing similar innovations, indicating sustained R&D investments.
- Its territorial scope, combined with potential for European or international extensions, gives broad market control until mid-2040.
- The patent’s strength relies on claims that are sufficiently broad to block generic or alternative compounds.
- Ongoing patent filings by competitors could influence freedom-to-operate post-2040.
FAQs
Q1: Can PT2056855 be challenged or invalidated before its expiration?
Yes. Legal challenges can be filed on grounds of lack of novelty, inventive step, or inadequate disclosure either through national courts or patent tribunals in Portugal.
Q2: Are there potential opportunities for patent term extensions?
In Portugal, patent term extensions are limited; however, supplementary protection certificates (SPCs) at the European level may extend market exclusivity for up to five years beyond the original expiry.
Q3: How does the patent protect against biosimilar or generic competition?
Claims covering specific chemical structures and methods serve as barriers, but complex biologics or highly similar compounds may produce around the patent via alternative routes unless additional patents or data exclusivities are secured.
Q4: What is the likelihood of patent infringement litigation?
High if competitors launch generics or biosimilars during the patent term, especially with broad claims. Companies typically monitor new patent filings and market entries.
Q5: How does this patent compare with similar patents in Europe?
PT2056855 aligns with European patent standards, with related filings likely covering broader geography. European patents generally have similar claim strength and enforceability but require separate validation.
References
- European Patent Office. (2022). Patent landscape reports.
- Portuguese Industrial Property Institute. (2022). Patent laws and regulations.
- WIPO. (2022). Patent application and examination procedures.
- Patent PT2056855 document. (Official Portuguese patent office records).
- Market and patent landscape analyses from industry reports.
